Please assess the completion status of the following clinical trial:

Trial Title: Blue Light for Treating Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent prior to any study-mandated procedure~2. Good health as determined by the Investigator according to physical examination~3. Willing and able to comply with study requirements~4. Skin type I-IV according to Fitzpatrick~5. Eczema, severity defined by an Eczema Area Severity Index (EASI)smaller/equal 20~6. Comparable clinical symptomatology of both intended treatment Areas~8. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intrauterine device \[IUD\] or transdermal contraceptive patch) 9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study~Exclusion Criteria:~1. Inmates of psychiatric wards, prisons, or other state institutions~2. Investigator or any other team member involved in the conduct of the clinical study~3. Participation in another clinical trial within the last 30 days~4. Pregnant and lactating women~5. Photodermatosis and/or Photosensitivity~6. Porphyria and/or hypersensitivity to porphyrins~7. Congenital or acquired immunodeficiency~8. Patients with any of the following conditions present on the study areas; Malignoma of the skin or severe actinic damage of the skin, atypical naevi or signs of hyperpigmentation, precancerosis viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin~9. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom- Syndrome)~10. Current diagnosis of exfoliative or toxic dermatitis.~11. Evidence of superinfection of the intended treatment areas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Blue light (Type: EXPERIMENTAL): Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
- Control (Type: NO_INTERVENTION): contralateral untreated control plaque on the same patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).